Dl-3-N-Butylphthalide Presents Anti-Cancer Activity in Lung Cancer by Targeting PD-1/PD-L1 Signaling

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.2159031912902
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: non–small cell lung cancer, version 4.2016. J Natl Compr Canc Netw. 2016;14(3):255–264. doi:10.6004/jnccn.2016.003126957612
   PubMed Web of Science ®Google Scholar
• Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010;107(9):4275–4280. doi:10.1073/pnas.091517410720160101
   PubMed Web of Science ®Google Scholar
• Conway JR, Kofman E, Mo SS, Elmarakeby H, Van Allen E. Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. Genome Med. 2018;10(1):93. doi:10.1186/s13073-018-0605-730497521
   PubMed Web of Science ®Google Scholar
• Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561. doi:10.3389/fphar.2017.0056128878676
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–461. doi:10.1016/j.ccell.2015.03.00125858804
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc323922437870
   PubMed Web of Science ®Google Scholar
• Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434–452. doi:10.1016/j.immuni.2018.03.01429562194
   PubMed Web of Science ®Google Scholar
• Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):328rv4. doi:10.1126/scitranslmed.aad7118
   PubMed Web of Science ®Google Scholar
• Xia L, Liu Y, Wang Y. PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions. Oncologist. 2019;24(S1):S31–S41. doi:10.1634/theoncologist.2019-IO-S1-s0530819829
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–1639. doi:10.1056/NEJMoa150764326412456
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–2028. doi:10.1056/NEJMoa150182425891174
   PubMed Web of Science ®Google Scholar
• Wang Q, Xu R. Immunotherapy-related adverse events (irAEs): extraction from FDA drug labels and comparative analysis. JAMIA Open. 2019;2(1):173–178. doi:10.1093/jamiaopen/ooy04530976759
   PubMedGoogle Scholar
• Varricchi G, Galdiero MR, Marone G, et al. Cardiotoxicity of immune checkpoint inhibitors. ESMO Open. 2017;2(4):e000247. doi:10.1136/esmoopen-2017-00024729104763
   PubMed Web of Science ®Google Scholar
• Tajiri K, Ieda M. Cardiac complications in immune checkpoint inhibition therapy. Front Cardiovasc Med. 2019;6:3. doi:10.3389/fcvm.2019.0000330729114
   PubMed Web of Science ®Google Scholar
• Liu RZ, Fan CX, Zhang ZL, et al. Effects of Dl-3-n-butylphthalide on cerebral ischemia infarction in rat model by mass spectrometry imaging. Int J Mol Sci. 2017;18:2451.
   PubMed Web of Science ®Google Scholar
• Tian X, He W, Yang R, Liu Y. Dl-3-n-butylphthalide protects the heart against ischemic injury and H9c2 cardiomyoblasts against oxidative stress: involvement of mitochondrial function and biogenesis. J Biomed Sci. 2017;24(1):38. doi:10.1186/s12929-017-0345-928619102
   PubMed Web of Science ®Google Scholar
• Li J, Li Y, Ogle M, et al. DL-3-n-butylphthalide prevents neuronal cell death after focal cerebral ischemia in mice via the JNK pathway. Brain Res. 2010;1359:216–226. doi:10.1016/j.brainres.2010.08.06120800583
   PubMed Web of Science ®Google Scholar
• Abdoulaye IA, Guo YJ. A review of recent advances in neuroprotective potential of 3-N-butylphthalide and its derivatives. Biomed Res Int. 2016;2016:5012341. doi:10.1155/2016/501234128053983
   PubMed Web of Science ®Google Scholar
• Amatore C, Jutand A. Anionic Pd(0) and Pd(II) intermediates in palladium-catalyzed heck and cross-coupling reactions. Acc Chem Res. 2000;33(5):314–321. doi:10.1021/ar980063a10813876
   PubMed Web of Science ®Google Scholar
• Wang HM, Zhang T, Huang JK, Sun XJ. 3-N-butylphthalide (NBP) attenuates the amyloid-beta-induced inflammatory responses in cultured astrocytes via the nuclear factor-kappaB signaling pathway. Cell Physiol Biochem. 2013;32:235–242. doi:10.1159/00035013923899885
   PubMedGoogle Scholar
• Hu Y, Bi X, Zhao P, Zheng H, Huang X. Cytotoxic activities, SAR and anti-invasion effects of butylphthalide derivatives on human hepatocellular carcinoma SMMC7721 cells. Molecules. 2015;20(11):20312–20319. doi:10.3390/molecules20111969926569212
   PubMed Web of Science ®Google Scholar
• Yang M, Dang R, Xu P, et al. Dl-3-n-butylphthalide improves lipopolysaccharide-induced depressive-like behavior in rats: involvement of Nrf2 and NF-kappaB pathways. Psychopharmacology. 2018;235:2573–2585. doi:10.1007/s00213-018-4949-x29943092
   PubMed Web of Science ®Google Scholar
• Zhao J, Liu J, Xu E, Liu Y, Xie A, Xiong H. dl-3-n-butylphthalide attenuation of methamphetamine-induced neurotoxicity in SH-SY5Y neuroblastoma cells. Life Sci. 2016;165:16–20. doi:10.1016/j.lfs.2016.09.00927640886
   PubMed Web of Science ®Google Scholar
• Liao D, Xiang D, Dang R, et al. Neuroprotective effects of dl-3-n-butylphthalide against doxorubicin-induced neuroinflammation, oxidative stress, endoplasmic reticulum stress, and behavioral changes. Oxid Med Cell Longev. 2018;2018:9125601. doi:10.1155/2018/912560130186550
   PubMed Web of Science ®Google Scholar
• Verdura S, Cuyas E, Cortada E, et al. Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity. Aging. 2020;12:8–34. doi:10.18632/aging.10264631901900
   PubMedGoogle Scholar
• Kang DY, Sp N, Jo ES, et al. The inhibitory mechanisms of tumor PD-L1 expression by natural bioactive gallic acid in Non-Small-Cell Lung Cancer (NSCLC) cells. Cancers. 2020;12:727.
   PubMed Web of Science ®Google Scholar
• Wang Z, Li MY, Zhang ZH, et al. Panaxadiol inhibits programmed cell death-ligand 1 expression and tumour proliferation via hypoxia-inducible factor (HIF)-1alpha and STAT3 in human colon cancer cells. Pharmacol Res. 2020;155:104727. doi:10.1016/j.phrs.2020.10472732113874
   PubMed Web of Science ®Google Scholar
• Jie M, Wu Y, Gao M, et al. CircMRPS35 suppresses gastric cancer progression via recruiting KAT7 to govern histone modification. Mol Cancer. 2020;19(1):56. doi:10.1186/s12943-020-01160-232164722
   PubMed Web of Science ®Google Scholar
• MacPherson L, Anokye J, Yeung MM, et al. HBO1 is required for the maintenance of leukaemia stem cells. Nature. 2020;577:266–270. doi:10.1038/s41586-019-1835-631827282
   PubMed Web of Science ®Google Scholar
• Quintela M, Sieglaff DH, Gazze AS, et al. HBO1 directs histone H4 specific acetylation, potentiating mechano-transduction pathways and membrane elasticity in ovarian cancer cells. Nanomedicine. 2019;17:254–265. doi:10.1016/j.nano.2019.01.01730759370
   PubMed Web of Science ®Google Scholar